ArticleESC heart failure2026
The HFpEF-ABA score predicts adverse cardiac remodelling and incident heart failure: a UK biobank study.
Article in ESC heart failure, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionThe HFpEF-ABA score (age, body mass index, atrial fibrillation) was originally derived to diagnose heart failure with preserved ejection fraction (HFpEF) in symptomatic patients. However, its utility as a preventive screening tool to identify preclinical risk in unselected community populations remains unvalidated.To validate the HFpEF-ABA score in a large community-based cohort free of heart failure and structural heart disease, utilizing a dual validation approach combining cardiac magnetic resonance phenotyping and long-term outcome prediction.
methodsWe analysed 416 374 UK Biobank participants without baseline heart failure. Participants were stratified by HFpEF-ABA score into low, intermediate, and high risk. We assessed biological validity in a subcohort of 65 293 participants utilizing cardiac magnetic resonance, and clinical validity via prospective adjudication of heart failure hospitalization over a median follow-up of 14.9 years.
resultsStructurally, elevated scores identified characteristic patterns of adverse cardiac remodelling in individuals at high risk for incident heart failure despite the absence of a clinical diagnosis: high-risk individuals exhibited profound left atrial dysfunction (LA ejection fraction 55.48% vs. 61.92%, P < .001) and distinct concentric ventricular remodelling compared with low-risk participants. Clinically, this structural substrate translated into a 6.4-fold excess risk of incident heart failure hospitalization (hazard ratio [HR] 6.44, 95% confidence interval [CI] 5.86-7.08, P < .001) and a 3.5-fold increased risk of the composite outcome (P < .001). The score demonstrated robust discrimination, outperforming its individual components.
conclusionThe HFpEF-ABA score demonstrates significant prognostic value for identifying individuals at high risk for incident heart failure and is associated with adverse cardiac remodelling and subclinical cardiac changes. These findings support repositioning the score from a diagnostic aid to a population-level screening instrument, supporting earlier identification of high-risk individuals before overt clinical heart failure develops.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.